Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Central Nervous System Infection Therapy
Reports outline central nervous system infection therapy study findings from Medical University of Vienna
November 19th, 2007
Scientists discuss in 'In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients' new findings in central nervous system infection. "Multi-resistant coagulase-negative staphylococci (CNS) may cause systemic infections in patients undergoing bone marrow transplantation. Daptomycin, a new lipopeptide, and tigecycline, a new glycylcycline, have excellent activity against Gram-positive bacteria including methicillin-resistant staphylococci," scientists writing in the European Journal of Haematology report. "This study presents the in vitro activity of daptomycin and tigecycline...
Source: Pain & Central Nervous System Week (2007-11-19)
|
